Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

ock-based compensation expense
  • Net loss of $8 million to $10 million
  • Basic and diluted net loss of $0.20 to $0.25 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Revenues:"We expect development revenues in 2013 will be comprised of approximately $19 million in committed R&D funding and license fee revenues from existing collaborations, and we anticipate $6 million to $9 million in additional license fees, R&D funding, milestones and cost reimbursements," Rogers noted. 

    "We forecast the vast majority of 2013 commercial revenues to be based on existing collaboration agreements.  While it remains difficult to forecast commercial revenues due to uncertainties around product launch timing, the number of product lines that will include our flavor ingredients, and other factors, we are currently estimating 2013 commercial revenues to be approximately $6 million.

    "2013 should prove to be a transitional year for Senomyx as we implement our direct sales strategy," Rogers stated.  "While direct sales are not expected to yield significant results in 2013, our goal is for direct sales to be a key driver of meaningful commercial revenues in future years.

    Expenditures:"Looking at expenditures, as we consider our resource requirements over the next several years for R&D, G&A and Commercial Operations, excluding the cost of commercial revenues, we expect we will be able to manage our expenses to be generally in-line with our 2013 expense guidance range, subject to quarterly fluctuations and increases for inflation.
    With respect to the expanded commercial organization activities in support of our direct sales strategy, many of the functions will be handled by existing Senomyx personnel.  In other cases, such as supply chain and account management, we will add dedicated resources to support these functions.
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    7. WuXi PharmaTech Announces Third-Quarter 2011 Results
    8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    9. Spherix Announces Third Quarter Financial Results
    10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will grow moderately through 2023 as the aging population, ... of dental biomaterials all spur procedure volumes. Growth will ... China and India ... within reach for a larger proportion of the population. ...
    (Date:12/17/2014)... The Activated Carbon Manufacturing ... why IBISWorld updated its original industry research report. ... an intensified focus on environmental policy. Over the five ... for power plants and a range of other industrial ... Analyst Sarah Kahn, “a range of downstream industrial sectors ...
    (Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
    (Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
    Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
    ... 3 Trials on Track for Initiation Later This Year ... at 8:30 a.m. Eastern Time -, SAN DIEGO, ... announced today that an independent Echocardiographic,Data Safety Monitoring Board ... ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and,Lorcaserin ...
    ... 11 GeneGo, Inc. and the Cystic,Fibrosis Foundation ... for the integration and analysis of cystic fibrosis ... and,algorithms for understanding the complex interconnected pathways that ... this collaboration will better help us to understand ...
    ... in October At U.S. Psychiatric Congress, PARSIPPANY, ... that it has acquired the unique Bipolar Disorder,treatment, ... EQUETRO(R) is a treatment for the acute manic ... condition where patients experience,extended periods of exaggerated highs ...
    Cached Biology Technology:Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 6GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis 2GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis 3Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R) 2
    (Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
    (Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
    (Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
    Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
    ... Inc. and AmberGen, Inc. announced today that ... whereby AmberGen will provide its proprietary photocleavable ... SomaLogic,s SOMAscanTM technology platform. The ... high-throughput proteomic quantitation platform is achieving sufficient ...
    ... of rainbow trout -- one in Alaska, the other in ... implications for fisheries conservation and management, an eight-member research team ... of development that has allowed these different salmomid subspecies to ... researchers, in a paper put online ahead of publication in ...
    ... a plant pathologist. His most recent research project revolved ... analyzed a special class of genes that encode cell ... these enzymes when attacking a plant. But while investigating ... came in different sizes in different individuals. To ...
    Cached Biology News:Genetic buzzer-beater genes may save fish 2Genetic buzzer-beater genes may save fish 3Shedding light on the 'dark matter' of the genome 2Shedding light on the 'dark matter' of the genome 3Shedding light on the 'dark matter' of the genome 4
    8 different frozen tissues are mounted on positively charged glass slides...
    ... The MEGAscript RNAi Kit ... of large mass amounts of ... in non-mammalian systems. The MEGAscript ... Ambions patented high-yield transcription technol-ogy ...
    ...
    ... VSO LF (Low Flow) offers the same benefits ... for applications where control is critical or flow ... valve automates the flow of gas in proportion ... DC current or pulse width modulation; closed loop ...
    Biology Products: